CXCL9 和 CXCL10 趋化因子作为主要为非裔美国注射吸毒者慢性丙型肝炎患者肝纤维化的预测因子。
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.
机构信息
Center for the Study of Hepatitis C, Division of Gastroenterology and Hepatology, Department of Medicine, Weill Cornell Medical College, New York, USA.
出版信息
J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.
Abstract
CXCL9 (monokine induced by IFN γ [Mig]) and CXCL10 (interferon [IFN] γ-inducible protein 10 [IP-10]) have been associated with hepatic fibrosis in predominantly white hepatitis C virus (HCV)-infected patients. We investigated their potential as noninvasive markers of hepatic fibrosis and fibrosis progression in African-American patients. Peripheral chemokine levels were measured in 115 HCV-infected patients within 4 months of liver biopsy; patients underwent a second biopsy after 3-5 years. CXCL10 levels appeared to be higher in patients with advanced fibrosis on the contemporaneous biopsy and were significantly higher in patients with advanced fibrosis compared with those with minimal fibrosis on the later biopsy (P = .0045). Therefore, CXCL10 has potential as a marker of fibrosis progression in African-American HCV-infected patients.
摘要
趋化因子 CXCL9（IFNγ 诱导的单核细胞因子[Mig]）和 CXCL10（IFNγ 诱导蛋白 10[IP-10]）与白人丙型肝炎病毒（HCV）感染患者的肝纤维化有关。我们研究了它们在非裔美国 HCV 感染患者中作为非侵入性肝纤维化和纤维化进展标志物的潜力。在肝活检后 4 个月内对 115 名 HCV 感染患者进行了外周趋化因子水平检测；3-5 年后，患者进行了第二次活检。在同期活检中，CXCL10 水平在纤维化程度较高的患者中似乎更高，与后来活检中纤维化程度最低的患者相比，纤维化程度较高的患者 CXCL10 水平显著更高（P=0.0045）。因此，CXCL10 有可能成为非裔美国 HCV 感染患者纤维化进展的标志物。
相似文献
1
CXCL9 and CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American injection drug users with chronic hepatitis C.CXCL9 和 CXCL10 趋化因子作为主要为非裔美国注射吸毒者慢性丙型肝炎患者肝纤维化的预测因子。
J Infect Dis. 2011 Sep 15;204(6):832-6. doi: 10.1093/infdis/jir424.
2
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.外周CXCR3相关趋化因子作为慢性丙型肝炎病毒感染中纤维化的生物标志物。
J Infect Dis. 2009 Dec 1;200(11):1774-80. doi: 10.1086/646614.
3
[THE ROLE OF CYTOKINES AND CHEMOKINES IN LABORATORY DIAGNOSTIC OF CHRONIC VIRAL HEPATITIS C].[细胞因子和趋化因子在丙型慢性病毒性肝炎实验室诊断中的作用]
Klin Lab Diagn. 2015 Aug;60(8):45-51.
4
Serum chemokine receptor CXCR3 ligands are associated with progression, organ dysfunction and complications of chronic liver diseases.血清趋化因子受体 CXCR3 配体与慢性肝病的进展、器官功能障碍和并发症有关。
Liver Int. 2011 Jul;31(6):840-9. doi: 10.1111/j.1478-3231.2011.02504.x. Epub 2011 Mar 10.
5
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.慢性丙型肝炎中，肝内CXCR3相关趋化因子水平与肝脏炎症及纤维化相关。
Hepatology. 2008 Nov;48(5):1440-50. doi: 10.1002/hep.22500.
6
Study of CXCL9-11 gene polymorphisms in liver fibrosis among patients with chronic hepatitis C.慢性丙型肝炎患者肝纤维化中 CXCL9-11 基因多态性的研究。
Pathog Dis. 2021 Mar 20;79(3). doi: 10.1093/femspd/ftab007.
7
Circulating levels of CXCL11 and CXCL12 are biomarkers of cirrhosis in patients with chronic hepatitis C infection.循环 CXCL11 和 CXCL12 水平是慢性丙型肝炎感染患者肝硬化的生物标志物。
Cytokine. 2019 May;117:72-78. doi: 10.1016/j.cyto.2019.02.006. Epub 2019 Feb 28.
8
High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity.在丙型肝炎病毒（HCV）感染患者中，无论二肽基肽酶4（DPP4）活性如何，血浆中高迁移率族蛋白（MIG，即CXCL9）水平较高有利于对聚乙二醇干扰素和利巴韦林产生反应。
Liver Int. 2016 Mar;36(3):344-52. doi: 10.1111/liv.12932. Epub 2015 Sep 6.
9
IP-10 can be measured in dried plasma spots in patients with chronic hepatitis C infection.IP-10 可在慢性丙型肝炎感染患者的干燥血浆斑中进行测量。
PLoS One. 2012;7(9):e45181. doi: 10.1371/journal.pone.0045181. Epub 2012 Sep 14.
10
Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection.血清趋化因子 CXC 配体 10（CXCL10）可预测丙型肝炎感染肝移植后的纤维化进展。
Hepatology. 2011 Feb;53(2):596-603. doi: 10.1002/hep.24098. Epub 2011 Jan 10.
引用本文的文献
1
The Protective Effects of Astaxanthin (AST) in the Liver of Weaned Piglets.虾青素（AST）对断奶仔猪肝脏的保护作用。
Animals (Basel). 2023 Oct 19;13(20):3268. doi: 10.3390/ani13203268.
2
Detection of Novel Biomarkers in Pediatric Autoimmune Hepatitis by Proteomic Profiling.通过蛋白质组学分析检测儿科自身免疫性肝炎的新型生物标志物。
Int J Mol Sci. 2023 Apr 19;24(8):7479. doi: 10.3390/ijms24087479.
3
HCV Core Protein Induces Chemokine CCL2 and CXCL10 Expression Through NF-κB Signaling Pathway in Macrophages.HCV 核心蛋白通过 NF-κB 信号通路诱导巨噬细胞中趋化因子 CCL2 和 CXCL10 的表达。
Front Immunol. 2021 Aug 31;12:654998. doi: 10.3389/fimmu.2021.654998. eCollection 2021.
4
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C.尽管早期治疗急性症状性丙型肝炎，但可溶性炎症环境中仍存在持久的印记。
J Infect Dis. 2022 Aug 26;226(3):441-452. doi: 10.1093/infdis/jiab048.
5
Elucidating Potential Profibrotic Mechanisms of Emerging Biomarkers for Early Prognosis of Hepatic Fibrosis.阐明新兴生物标志物早期预测肝纤维化的潜在抗纤维化机制。
Int J Mol Sci. 2020 Jul 3;21(13):4737. doi: 10.3390/ijms21134737.
6
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.人类免疫缺陷病毒合并感染丙型肝炎直接作用抗病毒药物期间的肝内病毒动力学：艾滋病临床治疗试验组 A5335S 子研究。
J Infect Dis. 2020 Jul 23;222(4):601-610. doi: 10.1093/infdis/jiaa126.
7
Plasma FABP4 is associated with liver disease recovery during treatment-induced clearance of chronic HCV infection.血浆 FABP4 与慢性 HCV 感染治疗诱导清除期间的肝病恢复相关。
Sci Rep. 2020 Feb 7;10(1):2081. doi: 10.1038/s41598-020-58768-z.
8
Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?丙型肝炎病毒对 CXCL10 分泌的免疫调节作用：CXCL10 能否成为慢性丙型肝炎的预后标志物？
J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
9
Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.撒哈拉以南非洲地区人类免疫缺陷病毒相关全身炎症和免疫激活的血浆生物标志物在抑制性抗逆转录病毒治疗之前和期间的变化。
J Infect Dis. 2019 Aug 9;220(6):1029-1033. doi: 10.1093/infdis/jiz252.
10
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection.疫苗接种前的血浆可溶性炎症指标水平可预测 HCV 和 HIV 感染患者对 HAV、HBV 和破伤风疫苗的反应。
Vaccine. 2018 Jan 25;36(4):453-460. doi: 10.1016/j.vaccine.2017.12.018. Epub 2017 Dec 16.
本文引用的文献
1
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection.外周CXCR3相关趋化因子作为慢性丙型肝炎病毒感染中纤维化的生物标志物。
J Infect Dis. 2009 Dec 1;200(11):1774-80. doi: 10.1086/646614.
2
Diagnosis, management, and treatment of hepatitis C: an update.丙型肝炎的诊断、管理与治疗：最新进展
Hepatology. 2009 Apr;49(4):1335-74. doi: 10.1002/hep.22759.
3
Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C.慢性丙型肝炎中，肝内CXCR3相关趋化因子水平与肝脏炎症及纤维化相关。
Hepatology. 2008 Nov;48(5):1440-50. doi: 10.1002/hep.22500.
4
The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.趋化因子在慢性丙型肝炎病毒感染中作为炎症介质的作用。
J Viral Hepat. 2007 Oct;14(10):675-87. doi: 10.1111/j.1365-2893.2006.00838.x.
5
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.α干扰素持续病毒学应答与丙型肝炎病毒相关肝硬化预后改善相关：一项回顾性研究。
Hepatology. 2007 Mar;45(3):579-87. doi: 10.1002/hep.21492.
6
Progression of liver fibrosis among injection drug users with chronic hepatitis C.慢性丙型肝炎注射吸毒者的肝纤维化进展
Hepatology. 2006 Apr;43(4):788-95. doi: 10.1002/hep.21091.
7
Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C.血浆趋化因子水平与丙型肝炎患者抗病毒治疗的结果相关。
Blood. 2005 Aug 15;106(4):1175-82. doi: 10.1182/blood-2005-01-0126. Epub 2005 Apr 28.
8
The natural history of hepatitis C.丙型肝炎的自然史
Semin Liver Dis. 2004;24 Suppl 2:3-8. doi: 10.1055/s-2004-832922.
9
Progression of fibrosis in chronic hepatitis C.慢性丙型肝炎中纤维化的进展
Gastroenterology. 2003 Jan;124(1):97-104. doi: 10.1053/gast.2003.50018.
10
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users.丙型肝炎病毒感染的注射吸毒者肝病的严重程度及其相关因素。
Hepatology. 2002 May;35(5):1247-55. doi: 10.1053/jhep.2002.33151.
Zotero 插件